All articles tagged with #novo nordisk
The Washington Post reports that some people with anorexia, bulimia, or binge eating disorder are using GLP-1 weight-loss medications, prompting alarm from doctors about safety and the need for careful monitoring of vulnerable patients, as anecdotal stories highlight the risk and complexity of treating eating disorders with these drugs.
New observational studies suggest GLP-1 weight-loss drugs like Ozempic and Mounjaro may slow cancer progression, lower recurrence, and improve breast-cancer survival, a finding that could bolster Novo Nordisk and Eli Lilly’s valuations as leaders in obesity/diabetes therapies.
Novo Nordisk beat Q1 estimates on strong Wegovy demand, posting $15.17 billion in revenue and $1.04 in adjusted EPS, and raised its 2026 outlook. The Wegovy pill launch contributed to early sales, with prescriptions surpassing 2 million since launch and more than $2.2 billion in first‑quarter Wegovy pill sales. Management now expects adjusted sales and operating profit to fall 4%–12% for the year, easing fears of a sharp slowdown in the obesity drug market, and the stock moved higher on the report.
Novo Nordisk CEO says the company is actively pursuing acquisitions to broaden its GLP-1 pipeline amid growing competition in obesity drugs, citing assets like CagriSema and zenagamtide; Wegovy's strong Q1 performance lifted full-year guidance, even as Eli Lilly overtook Novo in weekly GLP-1 market share.
Novo Nordisk raised its 2026 guidance after a strong Q1 powered by Wegovy, with U.S. Wegovy prescriptions around 1.3 million and Wegovy sales of 2.26 billion DKK; first-quarter sales rose 32% cc to 96.8 billion DKK and reported operating profit jumped 65%, though adjusted sales fell 4% and adjusted profit fell 6% excluding a $4.2 billion 340B-related adjustment. The company plans to launch Wegovy outside the U.S. in H2 2026, and the stock rose intraday but closed at a new five-year low amid competition in the GLP-1 weight-loss market.
Novo Nordisk’s Wegovy oral pill has gained strong early momentum since its January launch, aided by aggressive marketing and a lower monthly price, while Lilly’s Foundayo is ramping up more slowly. Telehealth platforms report rapid uptake for Wegovy, and investors are watching first-quarter results and potential international expansion as the GLP-1 pill market expands beyond injections.
Eli Lilly stock fell about 3.7% after Novo Nordisk extended its lead in the weight-loss drug race, with Lilly trading around $883.96 versus the prior close of $917.65.
Premarket, Eli Lilly shares fell after IQVIA data cited by Bloomberg showed Lilly’s obesity drugs Foundayo (oral) and Zepbound trailed Novo Nordisk’s Wegovy in weekly prescriptions; Zepbound fell about 2% week over week while Wegovy rose about 7% in the same period, and Foundayo posted 3,707 prescriptions in its first full week versus Wegovy’s roughly 18,410 in its first full week; analysts caution that one week of data isn’t definitive, but weak early momentum could pressure Lilly stock if the trend persists.
Doctors and patients using GLP-1 medications like Ozempic report emotional flattening—an oft-cited phenomenon dubbed the ‘Ozempic personality’—with everyday joys such as cake or sunsets feeling muted. Research is exploring whether GLP-1 drugs alter dopamine signaling or mood, but the underlying cause remains unclear and further study is needed.
Novo Nordisk launched a multi-month Wegovy subscription for its injectable doses and the high-dose pill, offering 3-, 6-, and 12-month plans with fixed monthly prices and potential savings up to $1,200/year for the injection and $600/year for the pill, via telehealth partners; the program aims to improve adherence and pre-empt competition from Eli Lilly’s upcoming oral GLP-1, and patients can opt out anytime (not yet on NovoCare DTC).
The FDA approved Novo Nordisk’s higher-dose Wegovy (7.2 mg) to improve weight loss outcomes, with phase 3 data showing about 20.7% average weight loss over 72 weeks; Novo plans an April launch to better compete with Eli Lilly’s Zepbound, which has demonstrated higher efficacy. A separate trial in obesity with Type 2 diabetes showed 14.1% weight loss, and the approval comes as the FDA pilots a faster review program for priority GLP-1 medications.
Exclusive accounts from Americans who suffered severe side effects after GLP-1 drugs Ozempic and Wegovy—ranging from blindness to extreme vomiting—shed light on potential dangers and are fueling lawsuits against Novo Nordisk.
The FDA issued a warning letter to Novo Nordisk for serious postmarketing adverse drug event reporting violations related to the GLP-1 drugs Ozempic and Wegovy, citing three deaths (including a suicide) and a stroke report; the agency said Novo Nordisk failed to report deaths within the 15-day window and did not adequately investigate or report the suicide, though authorities have recently found no proven link between GLP-1s and suicide. Novo Nordisk has 15 days to report adverse reactions and two weeks to describe corrective actions; the company says it is addressing the concerns.
The FDA sent Novo Nordisk a warning for serious lapses in reporting potential adverse events linked to semaglutide (the active ingredient in Ozempic and Wegovy), citing three deaths including a suicide and saying the company failed to investigate or report them within required timelines after an inspection of a New Jersey facility. Novo Nordisk says it will address the concerns, and the agency gave two weeks to outline corrective actions.
The FDA issued a Warning Letter to Novo Nordisk’s Plainsboro, New Jersey US headquarters after a January–February 2025 inspection found deficiencies in postmarketing adverse event surveillance and reporting under PADE, including issues with reporting timing and potential rejection of reports and insufficient root-cause analysis. Novo says it has a corrective action plan, has supplied seven progress updates, and remains confident it will address the regulator’s concerns. The letter follows a Form 483 and sits within broader U.S. regulatory scrutiny that includes other letters related to Ozempic/Wegovy and a Bloomington, Indiana facility, though the FDA states the warning does not judge drug quality or safety.